AAV2 Viral Vector Capsid Modification for Cardiomyocyte Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current viral vector particles based on AAV2 have limited specificity for cardiomyocytes and higher affinity for non-target cells like liver tissue, which hampers their effectiveness in gene therapy for cardiac diseases.
Innovation Solution
Development of AAV2 viral vector particles with modified capsid proteins containing specific amino acid sequences inserted at specific positions, enhancing tropism for cardiomyocytes while reducing transduction efficiency in liver cells, achieved by inserting amino acid sections between certain amino acid positions in the wild-type AAV2 capsid protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type AAV2 capsid protein is used, then the viral vector can transduce liver cells efficiently, but it has limited specificity for cardiomyocytes and higher affinity for non-target cells
Solution Approach 1:
The patent applies local quality by inserting specific amino acid sequences (peptides) at particular positions within the capsid protein structure. These localized modifications at specific regions of the capsid protein alter the binding properties to achieve cardiomyocyte-specific tropism while maintaining overall capsid function. The inserted peptides create localized interaction sites that selectively recognize cardiomyocyte surface receptors.
Solution Approach 2:
The patent changes the biochemical parameters of the capsid protein by inserting amino acid sequences that modify the protein's surface properties, charge distribution, and molecular recognition characteristics. These parameter changes transform the capsid's cell recognition profile from liver-preferential to cardiomyocyte-specific, altering the vector's tropism through controlled modification of protein composition.
2Reliability
If AAV9 is used, then high cardiac tropism is achieved, but the vector shows reduced expression compared to modified AAV2 variants
Solution Approach 1:
The patent creates composite capsid structures by combining the AAV2 capsid framework with inserted peptide sequences that confer cardiac-specific targeting. This composite approach merges the structural stability and immunogenicity advantages of AAV2 with the cardiac tropism properties, producing a hybrid vector that achieves both high cardiac specificity and superior transgene expression compared to wild-type AAV9.
3Reliability
If amino acid sequences are inserted into capsid protein, then specificity for cardiomyocytes is enhanced, but the structural complexity of the capsid increases
Solution Approach 1:
The patent applies segmentation by dividing the capsid protein into functional domains and inserting peptide sequences at specific boundaries or regions. This segmented approach allows the inserted sequences to function as independent modular elements that can be optimized for cardiac targeting without disrupting the overall capsid assembly and structural integrity. The modular insertion strategy simplifies the design and characterization process.
Data Source
AI summary
The invention provides a viral vector particle based on AAV2, which in its capsid protein (CAP) contains an inserted amino acid section which confers tropism for cardiomyocytes.